CINECA IRIS Institutional Research Information System

BORGHETTI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.297
NA - Nord America 654
SA - Sud America 245
EU - Europa 135
AF - Africa 17
Totale 3.348
Salva come PNG Salva come JPEG
Nazione #
CN - Cina 1.308
US - Stati Uniti d'America 632
SG - Singapore 456
HK - Hong Kong 308
BR - Brasile 209
VN - Vietnam 87
KR - Corea 57
IT - Italia 49
DE - Germania 17
AT - Austria 13
IN - India 13
AR - Argentina 12
BD - Bangladesh 12
RU - Federazione Russa 11
GB - Regno Unito 10
MX - Messico 10
EC - Ecuador 7
IQ - Iraq 7
JP - Giappone 7
MA - Marocco 7
SA - Arabia Saudita 7
CA - Canada 6
TR - Turchia 6
CO - Colombia 5
FI - Finlandia 5
NL - Olanda 5
PK - Pakistan 5
AZ - Azerbaigian 4
LT - Lituania 4
KE - Kenya 3
KZ - Kazakistan 3
PH - Filippine 3
PL - Polonia 3
SE - Svezia 3
TT - Trinidad e Tobago 3
ZA - Sudafrica 3
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
ES - Italia 2
FR - Francia 2
ID - Indonesia 2
IE - Irlanda 2
LB - Libano 2
PE - Perù 2
PY - Paraguay 2
TH - Thailandia 2
UA - Ucraina 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BM - Bermuda 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
LV - Lettonia 1
MZ - Mozambico 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
RW - Ruanda 1
SR - Suriname 1
TM - Turkmenistan 1
UG - Uganda 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.348
Salva come PNG Salva come JPEG
Città #
Shanghai 1.111
Hong Kong 308
Singapore 278
Santa Clara 218
Boardman 100
Hefei 85
Seoul 57
Ashburn 44
Ho Chi Minh City 35
Los Angeles 35
Beijing 22
Hanoi 18
São Paulo 17
Dallas 16
Redondo Beach 14
Nuremberg 13
Buffalo 11
New York 11
Chicago 10
Rio de Janeiro 9
Rome 7
Tokyo 7
Guarulhos 6
Mexico City 5
Wuhan 5
Baku 4
Belo Horizonte 4
Brasília 4
Jeddah 4
Lappeenranta 4
Osasco 4
Pescara 4
Secaucus 4
Thái Bình 4
Atlanta 3
Bắc Ninh 3
Canoas 3
Curitiba 3
Dhaka 3
Florence 3
Frankfurt am Main 3
Haiphong 3
Hyderabad 3
La Paz 3
Lucca 3
Misterbianco 3
Nairobi 3
Phoenix 3
Pisa 3
Porto Alegre 3
Quito 3
Ribeirão Preto 3
Stockholm 3
Vienna 3
Warsaw 3
Ankara 2
Baghdad 2
Betim 2
Blumenau 2
Brooklyn 2
Casablanca 2
Castellanza 2
Caxias do Sul 2
Changsha 2
Denver 2
Faisalabad 2
Genoa 2
Guangzhou 2
Guayaquil 2
Hải Dương 2
Itajaí 2
Itaquaquecetuba 2
Las Vegas 2
London 2
Lucknow 2
Manchester 2
Manila 2
Medellín 2
Miami 2
Montreal 2
Ningbo 2
Ninh Bình 2
Petrolina 2
Petrópolis 2
Qingdao 2
Raleigh 2
Recife 2
Riyadh 2
Salt Lake City 2
San Jose 2
San Juan 2
Santiago 2
Santo André 2
Shijiazhuang 2
São José do Rio Preto 2
Tampa 2
Toronto 2
Uberlândia 2
Vilnius 2
Xi'an 2
Totale 2.631
Salva come PNG Salva come JPEG
Nome #
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 483
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 263
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 166
Integrase inhibitors use and cmv infection predict immune recovery in people living with hiv starting first-line therapy 72
SARS-CoV-2 infection in a highly experienced person living with HIV 65
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 64
Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice 64
No significant changes in body fat mass in virologically suppressed, HIV- positive patients switched to lamivudine-dolutegravir 59
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 57
Cardiovascular disease risk in a cohort of virologically-suppressed PLWHIV switching to doravirine: preliminary data from the real life 57
Shall We Dance? Extending TANGO's Results to Clinical Practice 55
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 55
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 47
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak 45
Autochthonous dengue outbreak in Rome, Italy, in 2023 37
Cohort profile: the observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 35
Experienced PLWH switching to DOR/3TC/TDF in outpatient setting: real-word data on tolerability and Cost Savings from an Italian multicenter cohort 34
Investigating seroprevalence of IgG antibodies against Monkeypox Virus (MPXV) in a cohort of people living with HIV (PLWH) in Rome, during the 2022 outbreak: Moving beyond traditional at-risk populations 34
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 32
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 32
How do I manage disseminated Mycobacterium avium complex disease in people with HIV? 31
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 31
Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy 30
Toxoplasmosis mimicking CMV chorioretinitis in newly diagnosed PLWH: a case report 30
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 30
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 30
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 28
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 27
Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer breast receiving neoadjuvant chemotherapy 27
Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores 27
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 26
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 26
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort 26
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 26
Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis 25
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 25
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine 24
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 24
Are we really ready for dual therapy in naive people with HIV? The experience from a large university hospital in Rome, Italy 23
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice 20
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 20
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 20
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 20
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 20
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice 19
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 19
Is it time to re-think the use of etravirine in patients with available genotypic resistance test? 19
Focal status epilepticus as unique clinical feature of COVID-19: A case report 19
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 19
People Living with HIV in the COVID-19 Era: A Case Report. 19
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. 18
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey 18
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 18
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 18
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 18
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 17
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey 17
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 17
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 17
Kaposi-like manifestations in a newly diagnosed AIDS transgendered patient with silicone embolism syndrome and disseminated tuberculosis 17
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 17
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 17
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 17
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 16
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. 16
COVID-19 diagnosis does not rule out other concomitant diseases 16
Infections in hospitalised patients affected by end-stage diseases: a narrative overview 16
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 16
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 15
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 15
Atlas-M Study Group. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 15
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 15
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 15
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 15
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 15
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 15
Liver fibrosis is associated with cognitive impairment in people living with HIV 15
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 15
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 15
Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort StudyImpact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based 15
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 14
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 14
Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy 14
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 14
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study 14
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients 14
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 14
Dolutegravir plus lamivudine for the treatment of HIV-1 infection 14
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV. 14
ATLAS-M Study Group . Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 14
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV 14
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 13
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 13
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 13
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 13
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015 13
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 13
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 13
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 12
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 12
Totale 3.241
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.539
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024132 0 0 0 0 0 99 0 6 1 3 0 23
2024/20252.512 2 99 123 4 114 170 1.141 77 68 172 167 375
2025/2026861 62 267 150 155 156 71 0 0 0 0 0 0
Totale 3.505